A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET
A phase 1/2 trial of Selpercatinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) is a phase 1/2 interventional study registered as NCT03157128 by Eli Lilly and Company, with 857 participants enrolled, started 2017-05-02 and due to reach its primary completion in 2025-02-14. Interventions recorded: LOXO-292. Conditions listed: Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
- TrialA Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Selpercatinib, Eli Lilly (incl. Loxo), Non-small-cell lung cancer.
- TrialA Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
- TrialA Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Shares Eli Lilly (incl. Loxo), Small-cell lung cancer, Non-small-cell lung cancer.
- PersonAlexander Drilon
Shares Selpercatinib, Thyroid cancer, Non-small-cell lung cancer.
- TrialA Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE
Shares Eli Lilly (incl. Loxo), Small-cell lung cancer, Non-small-cell lung cancer.
- PersonLori J. Wirth
Shares Selpercatinib, Thyroid cancer.
- TrialLIBRETTO-431
Shares Selpercatinib, Non-small-cell lung cancer.